RESUMO
Symptoms related cow's milk proteins allergy (CMPA) usually improve between two to four weeks following an elimination diet, firstly with extensively hydrolyzed formulas (eHF). The aim of the EVA study was to observe the evolution of CMPA-related symptoms in real life after initiation of a whey-based extensively hydrolyzed formula (w-eHF, Althéra®, Nestlé Health Science, Switzerland). This cross-sectional prospective non-interventional study was carried out alongside paediatricians in private practice in France between June 2019 and June 2020. Infants aged 0−3 years presenting with confirmed diagnosis or clinical symptoms suggesting CMPA were enrolled. Data were collected at enrolment (baseline visit) and three to five weeks later (follow-up visit). Symptoms were assessed using the Cow's Milk-related Symptom Score (CoMiSS®). The per protocol population included 135 infants. The average number of symptoms per infant significantly decreased under the study formula (from 2.81 to 1.36, p < 0.001) and the proportions of infants with any CMPA related symptoms decreased. Daily crying and regurgitation showed the largest decline, respectively −44.4% and −31.85% (p < 0.001). These results describe the early management of symptoms suspected to be related to CMPA in routine practice that was rarely described in the literature. The number and severity of symptoms decreased most of the cases after commencing the study formula.
Assuntos
Hipersensibilidade a Leite , Animais , Bovinos , Feminino , Humanos , Estudos Transversais , Leite , Hipersensibilidade a Leite/diagnóstico , Estudos ProspectivosAssuntos
Hipersensibilidade Alimentar/dietoterapia , Hipersensibilidade Alimentar/tratamento farmacológico , Imunoglobulina E/sangue , Imunossupressores/efeitos adversos , Transplante de Fígado/efeitos adversos , Tacrolimo/efeitos adversos , Alérgenos/efeitos adversos , Alérgenos/imunologia , Pré-Escolar , Ciclosporina/administração & dosagem , Ciclosporina/uso terapêutico , Hipersensibilidade Alimentar/etiologia , Humanos , Terapia de Imunossupressão , Imunossupressores/administração & dosagem , Imunossupressores/uso terapêutico , Lactente , Hipersensibilidade a Noz/dietoterapia , Hipersensibilidade a Noz/tratamento farmacológico , Hipersensibilidade a Noz/etiologia , Testes CutâneosRESUMO
BACKGROUND: IL-2 has been reported to be critical for peripheral T(reg) survival in mouse models. Here, we examined T(reg) maintenance in a series of paediatric liver transplant recipients who received basiliximab, a therapeutic anti-CD25 monoclonal antibody. METHODOLOGY/PRINCIPAL FINDINGS: FoxP3+ CD4 T cells were analyzed by flow cytometry before liver grafting and more than 9 months later. We found that in vivo CD25 blockade did not lead to T(reg) depletion: the proportion of FoxP3+ cells among CD4 T cells and the level of FoxP3 expression were both unchanged. IL-2Rbeta expression was enhanced in FoxP3+ cells both before and after basiliximab treatment, while the level of IL-2Rgamma expression was similar in T(regs) and non-T(regs). No significant change in the weak or absent expression of IL-7Ralpha and IL-15Ralpha expression on FoxP3+ cells was observed. Although the proportion of FoxP3+ cells among CD4 T cells did not vary, food allergies occurred more rapidly after liver grafting in patients who received basiliximab, raising questions as to T(reg) functionality in vivo in the absence of functional CD25. CONCLUSIONS: CD25 appears non essential for human T(reg) peripheral maintenance in vivo. However, our results raise questions as to T(reg) functionality after therapeutic CD25 targeting.